Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- NRXP
- Price
- 2.34
- Stock movement up
- +0.08 (3.54%)
- Company name
- NRX Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 69.28M
- Ent value
- 102.84M
- Price/Sales
- 277.10
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 18.00
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- -33.71%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
NRXP does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 277.10 |
| Price to Book | - |
| EV to Sales | 411.37 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 29.61M |
| EPS (TTM) | -1.71 |
| FCF per share (TTM) | -0.56 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 250.00K |
| Gross profit (TTM) | 146.00K |
| Operating income (TTM) | -15.23M |
| Net income (TTM) | -38.06M |
| EPS (TTM) | -1.71 |
| EPS (1y forward) | 0.13 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 58.40% |
| Operating margin (TTM) | -6094.00% |
| Profit margin (TTM) | -15224.40% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 7.18M |
| Net receivables | 239.00K |
| Total current assets | 11.95M |
| Goodwill | 610.00K |
| Intangible assets | 1.78M |
| Property, plant and equipment | 419.00K |
| Total assets | 15.00M |
| Accounts payable | 4.26M |
| Short/Current long term debt | 347.00K |
| Total current liabilities | 40.59M |
| Total liabilities | 40.75M |
| Shareholder's equity | -25.75M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -12.50M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -12.50M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -253.81% |
| Return on Invested Capital | 148.87% |
| Cash Return on Invested Capital | 48.88% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.25 |
| Daily high | 2.38 |
| Daily low | 2.24 |
| Daily Volume | 612K |
| All-time high | 627.10 |
| 1y analyst estimate | 36.75 |
| Beta | 1.92 |
| EPS (TTM) | -1.71 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| NRXP | S&P500 | |
| Current price drop from All-time high | -99.63% | -0.89% |
| Highest price drop | -99.81% | -19.00% |
| Date of highest drop | 14 Nov 2024 | 8 Apr 2025 |
| Avg drop from high | -99.61% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
69.28M
Marketcap category
Small-cap
Description
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page